{
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "document": "FlublokPI",
  "verified_evidence": [
    {
      "id": 1,
      "quote": "Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.",
      "supports_claim": true,
      "explanation": "The quote directly supports the claim. It explicitly states that Study 6 (the pivotal trial) enrolled subjects 50 years and older and randomized them to receive either Flublok Quadrivalent or Fluarix Quadrivalent (a standard-dose quadrivalent vaccine) as an active control. The numbers of recipients for each group are also provided. This confirms that Flublok Quadrivalent was evaluated in a pivotal trial against Fluarix Quadrivalent, as the claim asserts.",
      "presence_explanation": "The quote appears on page 3 of the document, with only minor formatting differences and some OCR artifacts in the original. The key facts are all present: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.' The document text states: 'Study 6 (NCT02285998) enrolled subjects 50 years of age and older, randomized to receive Flublok Quadrivalent or Comparator (Fluarix Quadrivalent, manufactured by GlaxoSmithKline) as an active control [see Clinical Studies (14)]. The safety analysis population included 4328 Flublok Quadrivalent recipients and 4344 Comparator vaccine recipients.' This matches the quote in all substantive details.",
      "support_explanation": "The quote directly supports the claim. It explicitly states that Study 6 (the pivotal trial) enrolled subjects 50 years and older and randomized them to receive either Flublok Quadrivalent or Fluarix Quadrivalent (a standard-dose quadrivalent vaccine) as an active control. The numbers of recipients for each group are also provided. This confirms that Flublok Quadrivalent was evaluated in a pivotal trial against Fluarix Quadrivalent, as the claim asserts.",
      "original_relevance": "This quote explicitly states that Flublok Quadrivalent was evaluated in a trial (Study 6) where it was directly compared against Fluarix Quadrivalent, confirming that the pivotal trial involved these two vaccines."
    },
    {
      "id": 2,
      "quote": "The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 - [Attack rate Flublok Quadrivalent / Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). Antigenic and phylogenetic evaluations of the similarity (\"matching\") of clinical isolates to vaccine antigens were not performed. CDC epidemiological data for the 2014-2015 influenza season indicated that Influenza A (H3N2) viruses predominated and that most influenza A/H3N2 viruses were antigenically dissimilar while B viruses were antigenically similar to vaccine antigens during the 2014-2015 season. Study 6 met the pre-specified success criterion for the primary endpoint (lower limit of the 2-sided 95% CI of vaccine efficacy for Flublok Quadrivalent relative to Comparator should be not less than 10%).",
      "supports_claim": true,
      "explanation": "The quote, together with the surrounding text, directly supports the claim. It describes Study 6 as a pivotal trial evaluating Flublok Quadrivalent against a Comparator, and the document explicitly identifies this Comparator as Fluarix Quadrivalent. The quote details the efficacy endpoint, the calculation method, and the success criterion, all in the context of this head-to-head comparison. Therefore, the quote genuinely and explicitly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "presence_explanation": "The quote appears on page 4 of the document, with only minor formatting and wording differences due to OCR correction. The content is semantically equivalent: 'The primary efficacy endpoint of Study 6 was rtPCR-positive, protocol defined ILI due to any strain of influenza. Attack rates and relative vaccine efficacy (rVE), defined as 1 - [Attack rate Flublok Quadrivalent / Attack Rate Comparator], were calculated for the total efficacy population (n=8604) for the primary efficacy endpoint and for several alternative efficacy endpoints (Table 5). Antigenic and phylogenetic evaluations of the similarity (\"matching\") of clinical isolates to vaccine antigens were not performed. CDC epidemiological data for the 2014-2015 influenza season indicated that Influenza A (H3N2) viruses predominated and that most influenza A/H3N2 viruses were antigenically dissimilar while B viruses were antigenically similar to vaccine antigens during the 2014-2015 season. Study 6 met the pre-specified success criterion for the primary endpoint (lower limit of the 2-sided 95% CI of vaccine efficacy for Flublok Quadrivalent relative to Comparator should be not less than 10%).' The document also explicitly defines the Comparator as 'Fluarix Quadrivalent, manufactured by GlaxoSmithKline' in the same section.",
      "support_explanation": "The quote, together with the surrounding text, directly supports the claim. It describes Study 6 as a pivotal trial evaluating Flublok Quadrivalent against a Comparator, and the document explicitly identifies this Comparator as Fluarix Quadrivalent. The quote details the efficacy endpoint, the calculation method, and the success criterion, all in the context of this head-to-head comparison. Therefore, the quote genuinely and explicitly supports the claim that Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
      "original_relevance": "This quote describes the design and analysis of Study 6, specifying that Flublok Quadrivalent was compared to a 'Comparator' (previously defined as Fluarix Quadrivalent), directly supporting the claim that these two vaccines were evaluated against each other in the pivotal trial."
    },
    {
      "id": 3,
      "quote": "Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.",
      "supports_claim": true,
      "explanation": "The quote directly supports the claim. It explicitly defines the 'Comparator' in Study 6 as 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline.' It also states that Study 6 is registered as NCT02285998. This confirms that Flublok (quadrivalent) was evaluated in the pivotal trial (Study 6) against Fluarix (quadrivalent standard-dose vaccine), as the claim asserts.",
      "presence_explanation": "The quote appears on page 4 of the document, in the section discussing Study 6. The text reads: 'Abbreviations: rtPCR=reverse transcriptase polymerase chain reaction; Comparator=U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline; n=number of influenza cases; N=number of subjects in treatment group; RR=relative risk (Attack Rate Flublok/Attack Rate IIV4); rVE = [(1-RR) \u00d7 100]. *Study 6 is registered as NCT02285998.' This matches the quote provided, with only minor formatting differences (e.g., 'quad rival ent' vs 'quadrivalent' due to OCR), but all facts, numbers, and technical content are preserved.",
      "support_explanation": "The quote directly supports the claim. It explicitly defines the 'Comparator' in Study 6 as 'U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GlaxoSmithKline.' It also states that Study 6 is registered as NCT02285998. This confirms that Flublok (quadrivalent) was evaluated in the pivotal trial (Study 6) against Fluarix (quadrivalent standard-dose vaccine), as the claim asserts.",
      "original_relevance": "This quote provides the definition of 'Comparator' as Fluarix Quadrivalent, manufactured by GlaxoSmithKline, and links it to Study 6, confirming that Flublok Quadrivalent was evaluated against Fluarix Quadrivalent in the pivotal trial."
    },
    {
      "id": "comp_2",
      "quote": "Comparator, Fluarix Quadrivalent, manufactured by GlaxoSmithKline) (n=4489). Among randomized subjects, 58% were female, 80% white, 18% black/African-American, other races, and 5% of Hispanic/Latino ethnicity. A total of 5186 (60%) subjects w",
      "supports_claim": true,
      "explanation": "The quote directly states that the comparator in the pivotal trial (Study 6) was Fluarix Quadrivalent, manufactured by GlaxoSmithKline. This confirms that Flublok Quadrivalent was evaluated against Fluarix Quadrivalent in the pivotal trial, as the claim asserts. The quote is explicit and does not require inference.",
      "presence_explanation": "The quote appears on page 4 of the document: 'mpa rat or, Fluarix Quad rival ent, manufactured by Glaxo Smith kline) (n 4489). ong randomized subjects, 58% were female, 80% white, 18% black/African-Ameri other races, and 5% of Hispanic/Latino ethnicity. A total of 5186 (60%) subjects w'. This matches the quoted content in terms of meaning and data, despite minor OCR artifacts and word breaks. The key facts\u2014comparator is Fluarix Quadrivalent, manufactured by GlaxoSmithKline, and demographic breakdown\u2014are all present.",
      "support_explanation": "The quote directly states that the comparator in the pivotal trial (Study 6) was Fluarix Quadrivalent, manufactured by GlaxoSmithKline. This confirms that Flublok Quadrivalent was evaluated against Fluarix Quadrivalent in the pivotal trial, as the claim asserts. The quote is explicit and does not require inference.",
      "original_relevance": "This quote directly identifies the Comparator in Study 6 as Fluarix Quadrivalent, manufactured by GlaxoSmithKline, confirming that Flublok Quadrivalent was evaluated against Fluarix Quadrivalent in the pivotal trial."
    }
  ],
  "verification_stats": {
    "total_verified": 4
  },
  "image_evidence": []
}